Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

ECRC researchers developed a CRISPR-based gene therapy targeting dysferlin mutations in muscular dystrophy. By editing and ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...